December 21, 2007 - Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (NASDAQ: TTHI, TSX: TTH) announced that the first patient has been dosed in a Phase 2 clinical study of ELND005 (AZD-103) in patients with Alzheimer's disease... Transition Therapeutics' Press Release - Elan's Press Release -
